A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Not yet recruiting
Biogen
Phase 4
2022-05-27
The primary objective of this study is to verify the clinical benefit of monthly doses of
aducanumab in slowing cognitive and functional impairment as measured by changes in the
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in
participants with early Alzheimer's disease.
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.
Recruiting
InSightec
Early Phase 1
2022-07-01
The purpose of this study is to assess the safety and feasibility of administering standard
of care monthly Aduhelm (Aducanumab) infusion therapy in combination with opening the
blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild
Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.
Recruiting
Ali Rezai
Early Phase 1
2022-07-01
The purpose of this study is to assess the safety and feasibility of administering standard
of care monthly Aduhelm (Aducanumab) infusion therapy in combination with opening the
blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild
Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
